AstraZeneca to invest $3.5 billion in the US to expand global footprint
Britain's AstraZeneca will invest $3.5 billion in the US, its largest market, to expand its research and manufacturing footprint by the end of.
Drugs
Health
Pharma
Drugs
Health
Pharma
AstraZeneca’s drug to treat rare blood vessel disease gets EU nod
AstraZeneca Plc’s drug Fasenra got approval from the European Union regulator for treating adult patients with a rare inflammation of blood vessels.
Drugs
Health
Pharma
AstraZeneca, Daiichi’s Enhertu drug gets FDA’s priority review in US
AstraZeneca and Daiichi Sankyo got a priority review from the Food and Drug Administration for their Enhertu drug to treat a form of.
Drugs
Health
Pharma
AstraZeneca-Daiichi Sankyo’s breast cancer drug fails in late-stage trial
British-Swedish AstraZeneca and Japan's Daiichi Sankyo’s investigational drug for breast cancer failed to significantly improve the overall survival of the patients during an.
Drugs
Health
Pharma
AstraZeneca’s rare disease drug Fasenra gets US regulator’s nod
The US Food and Drug Administration approved AstraZeneca Plc’s Fasenra for treatment in adult patients with a rare inflammation of blood vessels.
Drugs
Health
Pharma
AstraZeneca’s asthma drug gets regulator’s approval in China
China’s drug regulator, the National Medical Products Association, has approved AstraZeneca Plc’s asthma drug.